SCL Science Targets 'Big Five' Hospitals With InnoSEAL Plus DL
6h agoen
From the article
SCL Science's InnoSEAL Plus DL hemostatic agent secured a treatment material code at Seoul St. Mary's Hospital, marking its entry into Korea's Big Five hospitals.
Continue reading on Seoul Economic DailyYou might also wanna read
Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax
clinicaltrials.gov·1d ago
Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
clinicaltrials.gov·8d ago
Pan-cancer AI atlas reveals diversity and spatial organization of tertiary lymphoid structures in tumors
Researchers built a pan-cancer atlas of tertiary lymphoid structures (TLSs) in human tumors, developing an AI-based framework to detect and
scim.ag·18d agoComparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
clinicaltrials.gov·3d ago
Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells
doi.org·13d ago
Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics
clinicaltrials.gov·3d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.